SVF
Level A· Stronger Clinical EvidenceSystematic Review

Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review.

Nilforoushzadeh MA., Heidari A., Ghane Y., Hosseini S., Azizi H., Najar Nobari N.

Systematic Review on Hair Regeneration, published in Arch Dermatol Res (2025) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Arch Dermatol Res (2025)
Country
Germany
Reported sample size
—
PMID
40014116
DOI
10.1007/s00403-025-03934-4

Abstract (original English)

Systemic sclerosis (SSc) and localized scleroderma (LoSc) are rare connective tissue diseases that are identified by skin thickening and hardening with different mechanisms of action. Although advancements in treatments have been achieved in recent years, these conditions remain a major cause of morbidity and currently lack a definitive cure. We sought to evaluate the efficacy and safety of platelet-rich plasma (PRP) treatment in individuals with LoSc and SSc. PubMed/Medline, Ovid-Embase, and Web of Science were systematically searched until December 27th, 2024. A citation search was also carried out, and clinical studies published in English were eligible to be included. A total of 11 studies utilized PRP to treat different conditions of scleroderma. In limited and diffuse forms of SSc, PRP resulted in the improvement of mouth handicap in systemic sclerosis (MHISS) items, skin elasticity, skin ulcer healing, and vascularization both alone and alongside hyaluronic acid, autologous fat, and stromal vascular fraction. Moreover, PRP injections led to a significant decrease in the LoSc cutaneous assessment tool (LoSCAT), as well as a reduction in pain and disease symptoms. Furthermore, patients with en coupe de sabre experienced hair regrowth after PRP treatment. The adverse effects, which can be limited or diffuse, were mild and self-limited. PRP contains a considerable number of

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansPlatelet-Rich PlasmaScleroderma, SystemicScleroderma, LocalizedTreatment OutcomeSkin
Hair & ScalpSystemic / IVHair Regeneration
View on PubMedDOI

Related research